{"entity":{"id":"paper-izutsu-ezh1-ezh2-inhibitor-atll-blood-2023","kind":"paper","name":"An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma","aka":["Izutsu 2023"],"tldr":"An oral drug blocking the enzymes EZH2 and EZH1 produced responses in 48 per cent of people with relapsed adult T-cell leukaemia/lymphoma, most of whom had already had mogamulizumab.","summary":"A multicentre phase 2 trial of valemetostat, an EZH2 and EZH1 inhibitor, 200 mg a day by mouth until progression or unacceptable toxicity, in relapsed or refractory aggressive adult T-cell leukaemia/lymphoma (acute, lymphoma and unfavourable chronic types). The primary endpoint was overall response assessed centrally by an independent efficacy assessment committee.","asOf":"2026-11-03","links":[{"label":"Blood 2023","url":"https://doi.org/10.1182/blood.2022016862"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/36150143/"},{"label":"Europe PMC","url":"https://europepmc.org/article/MED/36150143"}],"tags":["lymphoma-evidence-entities"],"related":[],"cancers":["adult-t-cell-leukaemia-lymphoma"],"sections":[],"technologies":[],"targets":["ezh2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["ds-3201b-atll-phase-2"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"Blood","year":2023,"doi":"10.1182/blood.2022016862","pmid":"36150143","authors":"Izutsu K, Makita S, Nosaka K, et al.","paperType":"observational","findings":["25 patients, median age 69, with a median of three prior lines; 24 had received mogamulizumab.","Centrally reviewed overall response was 48.0 per cent (90 per cent confidence interval 30.5 to 65.9), with 5 complete and 7 partial remissions.","In patients pretreated with mogamulizumab the overall response was 45.8 per cent.","The median duration of response was not reached."],"whatItMeans":"Activity after mogamulizumab, in a disease with few options at that point. Single-arm and small.","caveats":["Single arm, 25 patients, all in Japan."],"participants":25},"route":"/key-papers/paper-izutsu-ezh1-ezh2-inhibitor-atll-blood-2023/","neighbours":{"cancer":[{"id":"adult-t-cell-leukaemia-lymphoma","kind":"cancer","name":"Adult T-cell leukaemia/lymphoma","route":"/cancers/adult-t-cell-leukaemia-lymphoma/"}],"target":[{"id":"ezh2","kind":"target","name":"EZH2","route":"/targets/ezh2/"}],"trial":[{"id":"ds-3201b-atll-phase-2","kind":"trial","name":"EZH1 and EZH2 inhibitor DS-3201b in relapsed adult T-cell leukaemia/lymphoma","route":"/trials/ds-3201b-atll-phase-2/"}]}}